Literature DB >> 17355768

Diagnostic value of ultrasonographic examination for nonalcoholic steatohepatitis in morbidly obese patients undergoing laparoscopic bariatric surgery.

Ren-Jow Liang1, Hsih-Hsi Wang, Wei-Jei Lee, Phui-Ly Liew, Jaw-Town Lin, Ming-Shiang Wu.   

Abstract

BACKGROUND: There are few data relating to the role of fatty score (FS) and modified fatty score (MFS) in ultrasonographic (US) examination on the diagnosis of nonalcoholic steatohepatitis (NASH) in patients undergoing bariatric surgery.
METHODS: We investigated consecutive patients undergoing laparoscopic bariatric surgery with biopsy-proven nonalcoholic fatty liver disease. Patients with other liver diseases and significant alcohol consumption were excluded. Clinico-demographic and anthropometric data were collected before surgery. Each biopsy specimen was assessed by the same pathologist. Liver US examinations were performed by an independent and experienced sonographer before surgery. FS and MFS, determined by the US scoring system based on degrees of parenchymal echogenicity, far gain attenuation, gallbladder wall blurring, portal vein wall blurring and hepatic vein blurring, were used to assess the severity of fatty liver. US findings were correlated with histologic results.
RESULTS: Totally 101 patients were enrolled. The mean BMI of the patients was 44.6 +/- 5.4 kg/m(2). 29 patients (29%) were categorized with simple steatosis and 72 (71%) with NASH. FS and MFS were significantly correlated with the histological steatosis, fibrosis and the presence of NASH (P<0.001). A receiver operating characteristic curve identified the MFS of 2 as the best cut-off point for the prediction of NASH, yielding measures of sensitivity, specificity, positive predictive value, and accuracy for 72%, 86%, 93% and 76%, respectively. The positive likelihood ratio of 5.24 for MFS approximately doubled the post-test probability of NASH from 30% to 70%.
CONCLUSION: FS and MFS on US examination exhibit acceptable sensitivity and high specificity for the detection of the presence of NASH in morbidly obese patients and may aid in the selection of patients for closer follow-up or liver biopsy.

Entities:  

Mesh:

Year:  2007        PMID: 17355768     DOI: 10.1007/s11695-007-9005-6

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  28 in total

1.  Preoperative low energy diet diminishes liver size.

Authors:  Robert J Fris
Journal:  Obes Surg       Date:  2004-10       Impact factor: 4.129

2.  Change in liver size and fat content after treatment with Optifast very low calorie diet.

Authors:  Mark C Lewis; Madeleine L Phillips; John P Slavotinek; Lilian Kow; Campbell H Thompson; Jim Toouli
Journal:  Obes Surg       Date:  2006-06       Impact factor: 4.129

3.  Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass.

Authors:  Camilo Boza; Arnoldo Riquelme; Luis Ibañez; Ignacio Duarte; Enrique Norero; Paola Viviani; Alejandro Soza; Jose Ignacio Fernandez; Alejandro Raddatz; Sergio Guzman; Marco Arrese
Journal:  Obes Surg       Date:  2005-09       Impact factor: 4.129

4.  Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery.

Authors:  Cláudio Corá Mottin; Myriam Moretto; Alexandre Vontobel Padoin; Carlos Kupski; Aline Maria Swarowsky; Luiz Glock; Vinicius Duval; Jefferson Braga da Silva
Journal:  Obes Surg       Date:  2005 Jun-Jul       Impact factor: 4.129

5.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

7.  Ubiquitin as a marker of cell injury in nonalcoholic steatohepatitis.

Authors:  B F Banner; L Savas; J Zivny; K Tortorelli; H L Bonkovsky
Journal:  Am J Clin Pathol       Date:  2000-12       Impact factor: 2.493

8.  Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery.

Authors:  Florence Harnois; Simon Msika; Jean-Marc Sabaté; Charlotte Mechler; Pauline Jouet; Jeanine Barge; Benoit Coffin
Journal:  Obes Surg       Date:  2006-02       Impact factor: 4.129

9.  Cirrhosis: diagnosis with sonographic study of the liver surface.

Authors:  A Di Lelio; C Cestari; A Lomazzi; L Beretta
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

10.  The importance of routine liver biopsy in diagnosing nonalcoholic steatohepatitis in bariatric patients.

Authors:  Sherene Shalhub; Anna Parsee; Scott F Gallagher; Krista L Haines; Chris Willkomm; Stephen G Brantley; Haim Pinkas; Lisa Saff-Koche; Michel M Murr
Journal:  Obes Surg       Date:  2004-01       Impact factor: 4.129

View more
  20 in total

1.  Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery.

Authors:  Yosuke Seki; Satoru Kakizaki; Norio Horiguchi; Hiroaki Hashizume; Hiroki Tojima; Yuichi Yamazaki; Ken Sato; Motoyasu Kusano; Masanobu Yamada; Kazunori Kasama
Journal:  J Gastroenterol       Date:  2015-08-28       Impact factor: 7.527

2.  Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients.

Authors:  Anthony Petrick; Peter Benotti; G Craig Wood; Christopher D Still; William E Strodel; John Gabrielsen; David Rolston; Xin Chu; George Argyropoulos; Anna Ibele; Glenn S Gerhard
Journal:  Obes Surg       Date:  2015-12       Impact factor: 4.129

3.  Nonalcoholic fatty liver disease in morbidly obese subjects: correlation among histopathologic findings, biochemical features, and ultrasound evaluation.

Authors:  Everton Cazzo; Fabio de Felice Gallo; José Carlos Pareja; Elinton Adami Chaim
Journal:  Obes Surg       Date:  2014-04       Impact factor: 4.129

4.  An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Romina Lomonaco; Janet Chen; Kenneth Cusi
Journal:  Ther Adv Endocrinol Metab       Date:  2011-10       Impact factor: 3.565

5.  Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?

Authors:  Lucia Carulli; Stefano Ballestri; Amedeo Lonardo; Francesca Lami; Enrico Violi; Luisa Losi; Lisa Bonilauri; Anna Maria Verrone; Maria Rosaria Odoardi; Federica Scaglioni; Marco Bertolotti; Paola Loria
Journal:  Intern Emerg Med       Date:  2011-05-11       Impact factor: 3.397

6.  Visfatin levels in nonalcoholic fatty liver disease.

Authors:  Erdem Akbal; Erdem Koçak; Adnan Taş; Enver Yüksel; Seyfettin Köklü
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

7.  The HAALT Non-invasive Scoring System for NAFLD in Obesity.

Authors:  Harsh Sheth; Samir Bagasrawala; Mita Shah; Rais Ansari; A Olithselvan; Muffazal Lakdawala
Journal:  Obes Surg       Date:  2019-08       Impact factor: 4.129

8.  Oat prevents obesity and abdominal fat distribution, and improves liver function in humans.

Authors:  Hong-Chou Chang; Chien-Ning Huang; Da-Ming Yeh; Shing-Jung Wang; Chiung-Huei Peng; Chau-Jong Wang
Journal:  Plant Foods Hum Nutr       Date:  2013-03       Impact factor: 3.921

9.  Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects.

Authors:  Hsien-Liang Huang; Wen-Yuan Lin; Long-Teng Lee; Hsih-Hsi Wang; Wei-Jei Lee; Kuo-Chin Huang
Journal:  Obes Surg       Date:  2007-11       Impact factor: 4.129

10.  Serum α-fetoprotein levels in liver steatosis.

Authors:  Ayşegül Babalı; Erman Cakal; Tuğrul Purnak; Ibrahim Bıyıkoğlu; Başak Cakal; Osman Yüksel; Seyfettin Köklü
Journal:  Hepatol Int       Date:  2009-11-05       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.